About ICOR

The International CardioCel Outcomes Registry (ICOR) is a part industry funded Queensland led health services initiative that records outcome and performance data relating to surgery involving the use of ADAPT treated bovine pericardium (CardioCel). The ADAPT process was patented by Anteristech based in Malaga near Perth in Western Australia. CardioCel is marketed by LeMaitre Vascular, Inc, a leading global innovator, manufacturer and marketer of devices for the treatment of vascular disease. Le Maitre is headquartered in Burlington, MA, USA.

Collation and analysis of data in ICOR provides a real-time picture of the clinical outcomes associated with the use of CardioCel across the world and monitors how these outcomes change with time.

ICOR is managed by the Queensland Paediatric Cardiac Research (QPCR) team based at the Centre for Children's Health Research Centre in Brisbane, Australia. QPCR is affiliated with the Child Health Research Centre at the University of Queensland. ICOR is co-funded by the Children's Hospital Foundation and LeMaitre.